International Journal of Cancer Management

Published by: Kowsar

Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors

Mahmoud Parvin 1 , Parto Sabet-Rasekh 2 , Parastoo Hajian 2 , Peyman Mohammadi Torbati 1 , Parisa Sabet-Rasekh 2 and Hamidreza Mirzaei 2 , *
Authors Information
1 Department of Pathology, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Cancer Research Center, Shohada-e-Tajrish Hospital, Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: February 28, 2016, 9 (1); e4022
  • Published Online: February 23, 2016
  • Article Type: Research Article
  • Received: October 4, 2015
  • Accepted: January 21, 2016
  • DOI: 10.17795/ijcp-4022

To Cite: Parvin M, Sabet-Rasekh P, Hajian P, Mohammadi Torbati P, Sabet-Rasekh P, et al. Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors, Int J Cancer Manag. 2016 ; 9(1):e4022. doi: 10.17795/ijcp-4022.

Abstract
Copyright © 2016, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27(3): 289-93[PubMed]
  • 2. Nicholas J, Richard T, Bryan RV, Prashant P, Syed A. H. . Perez and Brady,s principies and practice of radiation oncology. 2013; : 1259-79
  • 3. Adam SF, Jason AE, Richard JL, Douglas MD, Dror M, Anthony LZ. Cancer principles and practice of oncology . 2015; : 896-916
  • 4. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am. 2000; 27(1): 1-13[PubMed]
  • 5. Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol. 2007; 190: 1-65[PubMed]
  • 6. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2): 127-37[DOI][PubMed]
  • 7. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol. 2008; 19(1): 73-80[PubMed]
  • 8. Wells A. Advances in Cancer Research. 1999; : 31-101
  • 9. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett. 1998; 425(1): 145-50[PubMed]
  • 10. Riedel F, Gotte K, Li M, Hormann K, Grandis JR. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol. 2002; 21(1): 11-6[PubMed]
  • 11. Eccles SA. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. Recent Results Cancer Res. 2000; 157: 41-54[PubMed]
  • 12. Chow NH, Liu HS, Lee EI, Chang CJ, Chan SH, Cheng HL, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 1997; 17(2B): 1293-6[PubMed]
  • 13. Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol. 1994; 101(2): 166-76[PubMed]
  • 14. Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985; 1(8425): 366-8[PubMed]
  • 15. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990; 65(7): 1619-25
  • 16. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res. 1990; 50(8): 2530-7[PubMed]
  • 17. Bue P, Wester K, Sjöström A, Holmberg A, Nilsson S, Carlsson J, et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer. 1998; 76(2): 189-93
  • 18. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer. 1994; 69(6): 1120-5
  • 19. Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer. 2007; 109(10): 2016-24[DOI]
  • 20. Jimenez RE, Hussain M, Bianco FJ, Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001; 7(8): 2440-7[PubMed]
  • 21. Wülfing C, Machiels JPH, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009; 115(13): 2881-90[DOI]
  • 22. Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson MA. Invasion of the bladder by transitional cell carcinoma. Cancer. 1998; 82(4): 715-23
  • 23. Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 62(2): 309-17
  • 24. Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol. 1995; 153(3 Pt 2): 919-25[PubMed]
  • 25. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 37: 9-15
  • 26. Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, et al. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol. 1993; 150(1): 126-31[PubMed]
  • 27. Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol. 1996; 155(1): 321-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments